Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more
Circio Holding ASA (CRNA) - Net Assets
Latest net assets as of June 2025: Nkr-12.40 Million NOK
Based on the latest financial reports, Circio Holding ASA (CRNA) has net assets worth Nkr-12.40 Million NOK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr12.75 Million) and total liabilities (Nkr25.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr-12.40 Million |
| % of Total Assets | -97.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1837.45 |
Circio Holding ASA - Net Assets Trend (2020–2024)
This chart illustrates how Circio Holding ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Circio Holding ASA (2020–2024)
The table below shows the annual net assets of Circio Holding ASA from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr-12.51 Million | +87.31% |
| 2023-12-31 | Nkr-98.54 Million | -3940.26% |
| 2022-12-31 | Nkr2.57 Million | -99.39% |
| 2021-12-31 | Nkr417.73 Million | +12.11% |
| 2020-12-31 | Nkr372.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Circio Holding ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67090400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr42.09 Million | % |
| Total Equity | Nkr-12.51 Million | 100.00% |
Circio Holding ASA Competitors by Market Cap
The table below lists competitors of Circio Holding ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anxo Pharmaceutical Co., Ltd.
TWO:6677
|
$16.90 Million |
|
HIPAY GROUP INH. EO 4-
F:9LH
|
$16.90 Million |
|
VULCAN MINLS
F:VM3
|
$16.91 Million |
|
Lii Hen Industries Bhd
KLSE:7089
|
$16.92 Million |
|
Openn Negotiation Limited
PINK:OPNNF
|
$16.90 Million |
|
Primega Group Holdings Limited
NASDAQ:ZDAI
|
$16.90 Million |
|
LiCycle Holdings Corp
NYSE:LICY
|
$16.90 Million |
|
Sino Green Land Corporation
PINK:SGLA
|
$16.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Circio Holding ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -98,541,000 to -12,509,000, a change of 86,032,000.
- Net income of 57,523,000 contributed positively to equity growth.
- Other factors increased equity by 28,509,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr57.52 Million | +459.85% |
| Other Changes | Nkr28.51 Million | +227.91% |
| Total Change | Nkr- | % |
Book Value vs Market Value Analysis
This analysis compares Circio Holding ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Nkr92.56 | Nkr5.30 | x |
| 2021-12-31 | Nkr66.55 | Nkr5.30 | x |
| 2022-12-31 | Nkr0.38 | Nkr5.30 | x |
| 2023-12-31 | Nkr-12.66 | Nkr5.30 | x |
| 2024-12-31 | Nkr-0.17 | Nkr5.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Circio Holding ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-3384.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -29.02% | -17327.88% | 0.00x | 1.40x | Nkr-145.38 Million |
| 2021 | -23.45% | 0.00% | 0.00x | 1.35x | Nkr-139.74 Million |
| 2022 | -16870.54% | -4328.11% | 0.10x | 39.13x | Nkr-433.15 Million |
| 2023 | 0.00% | -91821.95% | 0.00x | 0.00x | Nkr-103.09 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | Nkr58.77 Million |
Industry Comparison
This section compares Circio Holding ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $85,498,106
- Average return on equity (ROE) among peers: -134.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Circio Holding ASA (CRNA) | Nkr-12.40 Million | -29.02% | N/A | $16.90 Million |
| Arctic Bioscience AS (ABS) | $287.28 Million | -11.84% | 0.14x | $3.71 Million |
| Aqua Bio Technology ASA (ABTEC) | $8.32 Million | -176.71% | 0.95x | $7.08 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $76.32 Million |
| Circa Group AS (CIRCA) | $41.74 Million | -16.77% | 0.13x | $3.57 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.19 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.31 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $432.13K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.63 Million |
| Thor Medical ASA (TRMED) | $140.52 Million | -314.06% | 1.11x | $48.68 Million |